VIVAX BIO
Develops 3D bioprinters and bioprinted tissue constructs for medical research and cultivated meat, including the FABION bioprinter and in situ portable systems.
- CEO / Founder
- Yakov Balakhovsky
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $5.2M
- Latest Round
- Seed
- Key Investors
- 379 Number of Investors
Technology & Products
Key Products
FABION bioprinter; OrganAut bioprinter; In situ portable bioprinters; Bioprinted tissue and organ constructs; Tissue arrays
Technological Advantage
Proprietary bioprinting technologies for creating complex 3D tissue constructs; vertically integrated model from R&D to commercial manufacturing; early mover in space-based bioprinting applications.
Differentiation
Value Proposition
Enables rapid biofabrication of 3D tissue and organ constructs for drug discovery, disease modeling, and alternative protein production, reducing reliance on traditional 2D models and animal testing.
How They Differentiate
Offers a broader product range including both bioprinters and bioprinted tissues, with unique capabilities in microgravity bioprinting and cultivated meat applications, unlike competitors focused primarily on hardware or specific tissue models.
Market & Competition
Target Customers
Pharmaceutical companies, research institutions, cultivated meat producers
Industry Verticals
Biotechnology; Pharmaceutical; Medical Research; Cultivated Meat
Competitors
Cellink; Organovo (VivoSim Labs); Aspect Biosystems; Cyfuse Biomedical; Allevi
Growth & Milestones
Major Milestones
Launched OrganAut bioprinter to International Space Station in 2018 for microgravity bioprinting experiments; Printed and implanted murine thyroid gland construct in laboratory animals; Ranked among top 20 companies in global 3D bioprinting market